Editas Medicine stock gains as Q2 revenue reaches USD 11.89 million

Published on 10/06/2026 at 11:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Editas Medicine stock held USD 211.6 million in cash on June 30, 2026, with funding projected into the second half of 2028. Six analysts set a USD 5.80 average target.

EDIT, US28106W1036, Illustration mit AI erstellt.

Editas Medicine stock (ISIN US28106W1036) gained 6.49 percent to USD 2.79 on Nasdaq on October 5, 2026, with volume reaching 3,005,765 shares. The move puts the biotechnology company between its 52-week low of USD 1.66 and high of USD 4.54, while its Q2 figures and gene-editing pipeline remain central to the valuation.

Q2 revenue rises to USD 11.89 million

According to CEO.CA, Editas reported collaboration and research revenue of USD 11.9 million for the three months ended June 30, 2026, compared with USD 3.6 million in the same period of 2025. The company also reported a net loss of USD 18.2 million, or USD 0.15 per diluted share, versus a USD 53.2 million loss, or USD 0.63 per share, a year earlier.

The Q2 revenue figure exceeded the USD 2.85 million consensus estimate, while the USD 0.15 per-share loss was narrower than the USD 0.27 estimate, according to MarketBeat on October 5, 2026. That combination gives the stock a measurable earnings cushion, even though the company remains loss-making.

Cash runway supports EDIT-401

Editas held USD 211.6 million in cash and equivalents on June 30, 2026, compared with USD 146.6 million on December 31, 2025, according to CEO.CA. The company said that balance should fund operating expenses and capital spending into the second half of 2028, giving management room to advance EDIT-401 toward a Phase 1/2 study.

The program is designed as an in vivo gene-editing treatment for hyperlipidemia. Editas appointed Dan Ory as chief medical officer on September 8, 2026, to oversee clinical development as EDIT-401 moves toward the clinic, according to Editas Medicine.

Analysts see a higher valuation

Consensus remains constructive. PriceTargets lists a Moderate Buy rating from six analysts, with an average target of USD 5.80, a high target of USD 8.00 and a low target of USD 4.00.

Using the October 5 Nasdaq price of USD 2.79, the average target lies 107.9 percent above the price. MarketBeat reported that Guggenheim upgraded Editas from Neutral to Buy on September 23, 2026, and set a USD 5.00 target. The market is therefore balancing improved quarterly numbers and cash visibility against the clinical risk attached to an early-stage pipeline.

EDIT remains below its yearly high

EDIT was last at USD 2.79 on Nasdaq on October 5, 2026, with a market capitalization of USD 428.2 million and a daily high of USD 2.80. The stock remains USD 1.75 below its 52-week high of USD 4.54, leaving clinical execution and future data as the key valuation tests.